Biomarker ID | 1734 |
PMID | 30866497 |
Year | 2019 |
Biomarker | Methylation Status of DOCK2 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed [Log Fold Change: hsaâ€mirâ€891a (-4.8); hsaâ€mirâ€892a (-5.14); hsaâ€mirâ€1224 (-3.66); hsaâ€mirâ€93 (1.79); hsaâ€mirâ€23c (-2.96); hsaâ€mirâ€1251 (-2.76); hsaâ€mirâ€204 (-1.84); hsaâ€mirâ€323b (-2.31); hsaâ€mirâ€200c (1.58); hsaâ€mirâ€96 (1.98);] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Prostate Cancer Vs No Prostate Cancer |
Type of Biomarker | Diagnostic |
Cohort | 197 patients with Prostate cancer along with 37 normal samples (27 adjacent normal and 9 Benign Prostatic Hyperplasia) samples are chosen for the study |
Senstivity | 87.4% |
Specificity | 94.6% |
AUC | 0.9309 |
Accuracy | NA |
Level Of Significance | p < 0.001 |
Method Used | quantitative methylation specific PCR (qMSP) |
Clinical | No |
Remarks | Specificity fixed at 94.6%. Calculated sensitivity accordinly |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |